Circle Pharma announced publication of research in the Journal of Medicinal Chemistry highlighting optimization of oral cyclin A/B RxL inhibitors.

[button url="http://chem.colorado.edu/" color="blue"]Department of Chemistry and Biochemistry[/button] [button url="www.colorado.edu" color="blue"]University of ...

The induction of the cell cycle in cardiomyocytes involves the activation of specific genes that are responsible for regulating cell division and growth. Our laboratory has discovered several ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Cell cycle dysregulation in cancer cells represents a clinical option for treating cancer, by using cyclin-dependent kinase 4/6 (CDK4/6) inhibitory agents. Further evaluation on this approach was ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today announced a poster for preclinical data on CID-078, a ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today ...